Anlai Wang
Incyte
25 Papers
177 Citations
Anlai Wang is an academic researcher from Incyte. The author has contributed to research in topics: Chemokine receptor & CCR2. The author has an hindex of 12, co-authored 25 publications.
Chat about Author
Papers
Discovery and pharmacological characterization of a novel rodent-active CCR2 antagonist, INCB3344.
Carrie Brodmerkel,Reid Huber,Maryanne Covington,Sharon Diamond,Leslie Hall,Robert Collins,Lynn Leffet,Karen Gallagher,Patricia Feldman,Paul Collier,Mark Stow,Xiaomei Gu,Frédéric Baribaud,Niu Shin,Beth Thomas,Tim Burn,Greg Hollis,Swamy Yeleswaram,Kim Solomon,Steve Friedman,Anlai Wang,Chu Biao Xue,Robert C. Newton,Peggy Scherle,Kris Vaddi +24 more
TL;DR: It is demonstrated that therapeutic dosing of INCB3344 significantly reduces disease in mice subjected to experimental autoimmune encephalomyelitis, a model of multiple sclerosis, as well as a rat model of inflammatory arthritis, which support targeting this receptor for the treatment of chronic inflammatory diseases.
214
Discovery of INCB10820/PF-4178903, a potent, selective, and orally bioavailable dual CCR2 and CCR5 antagonist
Changsheng Zheng,Ganfeng Cao,Michael Xia,Hao Feng,Joseph Glenn,Rajan Anand,Ke Zhang,Taisheng Huang,Anlai Wang,Ling Kong,Mei Li,Laurine G. Galya,Robert Hughes,Rajesh V. Devraj,Phillip A. Morton,D. Joseph Rogier,Maryanne Covington,Fred Baribaud,Niu Shin,Peggy Scherle,Sharon Diamond,Swamy Yeleswaram,Kris Vaddi,Robert C. Newton,Greg Hollis,Steven Friedman,Brian Metcalf,Chu-Biao Xue +27 more
TL;DR: It is reported the discovery of a potent, selective, and orally bioavailable dual CCR2 and CCR5 antagonist (3S,4S)-N-[(1R,3S)-3-isopropyl-3- isopropymethoxytetrahydro-2H-pyran-4-amine (19).
52
Patent
3-cycloalkylaminopyrrolidine derivatives as modulators of chemokine receptors
Chu-Biao Xue,Brian Metcalf,Han Amy Qi,Robinson Darius J,Changsheng Zheng,Anlai Wang,Yingxin Zhang +6 more
- 16 Dec 2004
TL;DR: The 3-cycloalkylaminopyrrolidine derivatives of the formula 1: (wherein R1, R2, R3, R4, R5, R6, R7, X, Y and Z are as defined herein) are useful as modulators of chemokine receptor activity as discussed by the authors.
40
Discovery of INCB9471, a Potent, Selective, and Orally Bioavailable CCR5 Antagonist with Potent Anti-HIV-1 Activity.
Chu-Biao Xue,Chen Lihua,Ganfeng Cao,Ke Zhang,Anlai Wang,Meloni David,Joseph Glenn,Rajan Anand,Michael Xia,Ling Kong,Taisheng Huang,Hao Feng,Changsheng Zheng,Mei Li,Laurine G. Galya,Jiacheng Zhou,Niu Shin,Fredric Baribaud,Kim Solomon,Peggy Scherle,Bitao Zhao,Sharon Diamond,Tom Emm,Douglas Keller,Nancy Contel,Swamy Yeleswaram,Kris Vaddi,Gregory Hollis,Robert C. Newton,Steven Friedman,Brian Metcalf +30 more
TL;DR: Modification on the indane ring led to the discovery of compound 22a (INCB9471) that exhibited high affinity for CCR5, potent anti-HIV-1 activity, high receptor selectivity, excellent oral bioavailability, and a tolerated safety profile.
20
Patent
Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors
Yun-Long Li,David M. Burns,Hao Feng,Chu-Biao Xue,Anlai Wang,Jun Pan +5 more
- 14 Jan 2014
TL;DR: In this article, the authors describe bicyclic aromatic carboxamide derivatives, as well as their compositions and methods of use, which are useful in the treatment of diseases related to the activity of Pim kinases including, e.g., cancer and other diseases.
18